Introduction
============

Inter- and intraindividual variability in the expression and activity of drug metabolizing enzymes, transporters and their regulators is a major determinant of drug response, both in terms of drug efficacy and adverse events. The cytochrome P450 enzymes, a superfamily of microsomal and mitochondrial hemoproteins (CYP), are particularly variable between and within subjects ([@B58]). Despite half a century of pharmacogenetic research, much of the interindividual variation remains unexplained ([@B37]; [@B30]). This "dark variation" may be explained by so far unidentified or unexplored genes that influence drug metabolism at the level of protein-protein interactions (PPI). The multiple monooxygenase functions of microsomal CYP enzymes strictly depend on PPI with the single microsomal flavoprotein NADPH:cytochrome P450 oxidoreductase (POR) to allow electron transfer from NADPH to the heme iron ([@B46]; [@B23]). Since POR is present in the endoplasmic reticulum (ER) at sub-stoichiometric amounts compared to CYP, it has been proposed that their interactions involve transient oligomeric complexes ([@B4]). In contrast to POR, the small hemoprotein cytochrome b5 (CYB5), which is located together with CYB5-reductase and the other components on the cytoplasmic side of the ER, is not an obligatory electron donor for CYPs but acts as modulator of enzyme activity in CYP- and sometimes substrate-dependent way ([@B17]). For a long time, POR and CYB5 were the only proteins known to functionally interact with CYPs during the microsomal monooxygenase reaction. Only in recent years new PPI candidates for cytochromes P450 have been considered (see other articles in this Research Topic).

A particularly intriguing group of proteins are the so-called "membrane-associated progesterone receptor" (MAPR) proteins. The term emphasizes their common ability to bind progesterone and to elicit rapid steroidal effects independent of the classical steroid hormone receptors ([@B54]; [@B38]). Following the initial purification of a high-affinity progesterone-binding protein (later termed progesterone receptor membrane component 1, PGRMC1) from porcine liver membranes and cDNA cloning ([@B36]; [@B12]), MAPRs were recognized as evolutionarily conserved, distant homologs of CYB5, that can principally interact with CYPs and modulate their functions ([@B40]; [@B18]).

The purpose of this review is to provide an overview and critical assessment of the studies elucidating potential interactions of MAPRs with CYPs. Apart from this, MAPRs interact with an increasing number of different proteins and are involved in a wide variety of cellular functions including cholesterol and steroid homeostasis, cell cycle regulation, cell migration, neurogenesis, autophagy, heme homeostasis and more that are only briefly mentioned but not the focus of this review. Readers interested in these aspects are referred to excellent reviews by others ([@B33]; [@B2]; [@B26]; [@B43]; [@B7]; [@B16]).

Molecular, Biochemical and Cellular Properties of Maprs
=======================================================

The four MAPR proteins PGRMC1, PGRMC2, neuferricin and neudesin share a homologous CYB5-like heme/steroid-binding domain but lack homology with the classical nuclear or membrane-bound steroid receptors ([@B38]; [@B39]; [@B26]). Recent crystallographic analyses confirmed the hemoprotein nature of PGRMC1 with a special five-coordinated heme iron involving Tyr113, as opposed to the six-coordinated heme with two axial histidines in CYB5 ([@B39]; [@B22]; [@B21]). Interestingly, this difference allows human PGRMC1 to form stable homodimers through hydrophobic heme-heme stacking interactions, explaining earlier observations of dimeric complexes ([@B40]; [@B21]). Since the heme-binding residues are conserved among MAPRs, these proteins may all share the ability of heme-dependent homo- and/or heterodimerization ([@B47]). Although PGRMC1 had originally been defined as a component of a progesterone-binding protein complex with affinities in the nM range ([@B36]), it remained questionable whether progesterone actually binds directly to PGRMC1 itself. A recent study provided first qualitative spectroscopic evidence that this is indeed the case, while it is still not proven for other MAPRs ([@B22]).

PRGMC1
------

PRGMC1 is predominantly expressed in mammalian liver and kidney but also found in steroidogenic and reproductive tissues, brain, breast, heart, lung, skeletal muscle, pancreas, and other organs ([@B12]; [@B26]). Typically it is colocalized with CYPs in the smooth ER, but it has also been localized in the nucleus, cytoplasm, plasma membrane, and mitochondria ([@B26]; [@B48]). Expression is inducible by carcinogens, including dioxin ([@B51]), and increased in breast and other tumors, where it contributes to cancer progression ([@B42]; [@B50]). Reported physiological functions affected by PGRMC1 include cholesterol/steroid biosynthesis and metabolism (see below), iron homeostasis and heme trafficking by regulating hepcidin expression and ferrochelatase activity ([@B10]; [@B31]; [@B48]), promotion of autophagy through interaction with MAP1LC3B ([@B41]), regulation of cell cycle, proliferation, and cell death ([@B47]), maintenance of female reproductive functions in PGRMC1 conditional knock-out mice ([@B35]), cell migration and invasion ([@B52]), amyloid beta binding and synaptotoxicity in a mouse model of Alzheimer's disease ([@B20]), and others ([@B33]; [@B2]; [@B43]; [@B7]; [@B16]). A growing number of studies supports furthermore a role of PGRMC1 in drug response and as potential drug target, e.g., by increasing susceptibility to tyrosine kinase inhibitors ([@B1]), decreasing doxorubicin cytotoxicity ([@B32]), or mediating atypical antipsychotic drug-induced lipid disturbances ([@B8]). Importantly, in 2011 PGRMC1 was identified as the elusive sigma 2 receptor (S2R), an intracellular orphan receptor that binds to many drugs and that is abundant in liver and kidney ([@B57]; [@B2]).

PGRMC2
------

PGRMC2 harbors a structurally similar CYB5 domain as PGRMC1, while there are differences in the N-terminal transmembrane domain ([@B6]). Human PGRMC2 protein is 247 amino acids in length. Despite its structural similarities to PGRMC1, PGRMC2 has been less well studied ([@B55]; [@B16]). Expression appears to be ubiquitous with similar intracellular localization ([@B9]; [@B19]). In SKOV-3 ovarian cancer cells no differences between PGRMC1 and 2 in regard to cell viability or response to cisplatin and progesterone were found, but only PGRMC2 inhibited cell migration ([@B3]). PGRMC2 was also implicated in cell cycle regulation ([@B47]).

Neudesin
--------

Neudesin was originally identified as a mouse secreted protein with neurotrophic activity and termed neuron-derived neurotrophic factor (NENF) ([@B27]). In adult mice, neudesin was expressed preferentially in the CNS spinal cord but also in several peripheral tissues ([@B27], [@B26]). NMR studies suggested a similar structure with a potential heme-binding pocket ([@B14]). The physiological roles of neudesin as a secreted protein appear to be significantly different from PGRMC1/2, including particularly neurotrophic activity that required heme binding and was mediated through mitogen-activated protein (MAP) and phosphatidylinositol 3-kinase (PI-3K) pathways ([@B27]). Several neurological functions have been studied in knockout mice as summarized elsewhere ([@B45]). Extracellular/secreted neudesin may be involved in carcinogen resistance and tumor cell immortalization, although specific receptors remain unknown ([@B45]).

Neuferricin
-----------

Neuferricin (CYP5D2) was discovered *via* a homology-based search of the CYB5-like heme/steroid-binding domain of neudesin, alternatively termed cytochrome B5 Domain Containing 2 (CYB5D2) ([@B25]). Neuferricin is also widely expressed in several tissues including the CNS, heart, adrenal glands, and kidneys. Human neuferricin is 264 amino acids in length and includes a cleavable signal sequence at its N terminus followed by a heme-binding domain that may involve aspartic acid (D86) instead of tyrosine in heme binding ([@B5]). CYB5D2 can be detected as secreted hemoprotein in some cell lines but also colocalized with POR in the ER ([@B56]; [@B5]). Ectopic CYB5D2 expression inhibited cell proliferation and anchorage-independent colony growth of HeLa cells ([@B5]).

Specific Involvement of Maprs in CYP Functions
==============================================

The available evidence suggesting that MAPR proteins can interact with the microsomal CYP-monooxygenase system to modulate its function is based on different species from yeast to human, various experimental systems, and relates to CYP enzymes catalyzing steroidogenic or xenobiotic reactions (**Table [1](#T1){ref-type="table"}**). The levels of interactions may include not only physical PPIs but also indirect influences via heme transfer, heme and iron homeostasis, and transcriptional regulation (**Figure [1](#F1){ref-type="fig"}**).

###### 

Functional interactions between membrane-associated progesterone receptors (MAPR) proteins and cytochrome P450 system.

  MAPR                            CYP                         System                                                            Enzymatic activity                                                Direction of influence   Reference
  ------------------------------- --------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ------------------------ ---------------
  IZA/PGRMC1 (rat)                CYP21A2 (rat)               Inhibition by anti-IZA monoclonal antibody                        Progesterone 21-hydroxylase                                       Activation               [@B29]
  IZA/PGRMC1 (rat)                CYP21A2 (rat)               COS-7 cell coexpression                                           Progesterone 21-hydroxylase                                       Activation               [@B40]
  IZA/PGRMC1 (rat)                CYP17 (guinea pig)          COS-7 cell coexpression                                           Progesterone 17α-hydroxylase                                      Little or no influence   [@B39]
  IZA/PGRMC1 (rat)                CYP17 (guinea pig)          COS-7 cell coexpression                                           17α-Hydroxyprogesterone 17--20 lyase                              Activation               [@B39]
  IZA/PGRMC1 (rat)                CYP11B1 (rat)               COS-7 cell coexpression                                           Progesterone 11β-hydroxylase                                      Little or no influence   [@B40]
  PGRMC1 (human)                  CYP19A1 (human)             CYP19-engineered MCF-7 human breast cancer cells RNAi knockdown   Androst-4-ene-3,17-dione conversion                               Activation               [@B2]
  Dap1/PGRMC1 (*S. cerevisiae*)   CYP51A1 (*S. cerevisiae*)   *S. cerevisiae* genetics                                          Lanosterol-14-demethylase                                         Activation               [@B15] [@B34]
  Dap1/PGRMC1 (*S. pombe*)        CYP51A1 (*S. pombe*)        *S. pombe* strain lacking DAP1                                    Lanosterol-14-demethylase                                         Activation               [@B18]
  Dap1/PGRMC1 (*S. pombe*)        CYP61A1 (*S. pombe*)        *S. pombe* strain lacking DAP1                                    Lanosterol-22-desaturase                                          Activation               [@B18]
  PGRMC1 (rabbit)                 CYP2C2 (rabbit)             HEK293, HepG2 cell coexpression                                   Luciferin 6′ methyl ether *O*-demethylation                       Inhibition               [@B53]
  PGRMC1 (human)                  CYP2C8 (human)              HEK293, HepG2 cell coexpression                                   Luciferin 6′ methyl ether *O*-demethylation                       Inhibition               [@B53]
  PGRMC1 (human)                  CYP3A4 (human)              HEK293, HepG2 cell coexpression                                   Luciferin 6′ pentafluorobenzyl ether depentafluorobenzylation     Inhibition               [@B53]
  PGRMC1 (human)                  CYP2C9 (human)              HepG2 coexpression, human hepatocytes RNAi knockdown              *S*-Warfarin 7-hydroxylase and diclofenac 4′-hydroxylase          Inhibition               [@B44]
  PGRMC1 (human)                  CYP3A4 (human)              HepG2 coexpression, human hepatocytes RNAi knockdown              Testosterone 6β-hydroxylase and midazolam 1′-hydroxylase          Inhibition               [@B44]
  PGRMC1 (human)                  CYP2E1 (human)              HepG2 coexpression, human hepatocytes RNAi knockdown              Chlorzoxazone 6-hydroxylase and 7-ethoxycoumarin *O*-deethylase   No influence             [@B44]
  PGRMC2 (human)                  CYP3A4 (human)              Human liver genetic association                                   Atorvastatin 2-hydroxylase                                        Inhibition               [@B28]
  CYB5D2 (human)                  CYP3A4 (human)              Hela cell expression and RNAi knockdown                           Luciferin 6′ pentafluorobenzyl ether depentafluorobenzylation     Activation               [@B5]

![**Confirmed and hypothetical interactions of membrane-associated progesterone receptors (MAPRs) with microsomal cytochrome P450 (CYP) system.** MAPR proteins located in the endoplasmic reticulum (ER) membrane can directly interact with each other to form homo- and heterodimers; MAPR monomers and dimers may participate in PPIs with P450 oxidoreductase (POR), cytochrome b5 (CYB5) and/or CYPs. Transfer of heme to CYB5 and possibly CYPs as well as involvement in iron/heme homeostasis may influence heme integration and thus CYP function. Furthermore, MAPRs participate in diverse signaling pathways that may affect transcriptional regulation of CYP gene expression (double arrows, confirmed protein-protein interactions; solid arrows, confirmed influence; dashed arrows, hypothetical influence).](fphar-08-00159-g001){#F1}

PGRMC1
------

First indications for a link between PGRMC1 and CYP function came from two independent studies. Identification of the adrenal "inner zone antigen" (IZA) as a MAPR member ([@B49]), its localization in both steroidogenic and steroid metabolizing tissues and the fact that an anti-IZA monoclonal antibody decreased certain adrenal steroidhydroxylase activities led the authors to suggest a function in steroid hormone biosynthesis and/or metabolism ([@B40]). By coexpressing IZA/PGRMC1 with CYP21A2, CYP11B1 or CYP17 in COS-7 cells they found differential effects, namely enhancement of progesterone 21-hydroxylation, no effect on progesterone 11β- or 17α-hydroxylation, and activation of the CYP17-catalyzed 17--20 lyase reaction ([@B40], [@B39]). About at the same time a search for novel yeast genes involved in DNA damage response led to the identification of *Dap1* ([@B15]). Steroid analyses of *Saccharomyces cerevisiae* yeast cells lacking *Dap1* revealed decreased levels of ergosterol but increased levels of its intermediates, suggesting a partial defect in sterol synthesis by lanosterol-14-demethylase, the highly conserved yeast-essential Erg11/CYP51 ([@B15]). Genetic follow-up studies supported a model in which heme binding by Dap1 is required to activate Erg11/CYP51, although a Dap1-Erg11 complex could not be directly detected by immunoprecipitation experiments ([@B34]).

Further evidence for a role of Dap1/PGRMC1 in CYP function was provided by [@B18] working with *Schizosaccharomyces pombe*. After confirming that fission yeast Dap1 is also a hemoprotein and directly binds to and activates enzymatic activities of CYP51A1 (Erg11) and CYP61A1 (Erg5), they investigated whether PGRMC1 is required for cholesterol synthesis in mammals ([@B18]). RNA interference-mediated knock-down of hPGRMC1 in HEK293 cells resulted in lanosterol accumulation, indicating that PGRMC1 was required for the demethylation of lanosterol by the Erg11 homolog, CYP51A1. Using a coexpression/coimmunoprecipitation approach PGRMC1 was shown to form a stable complex with CYP51A1 ([@B18]). The authors applied the latter experiment also to CYP7A1, CYP21A2, and CYP3A4, demonstrating physically stable PGRMC1-CYP complexes in all cases. PGRMC1 was later shown to also activate CYP19 aromatase ([@B2]). Collectively these studies strongly suggest the ability of PGRMC1 to form functional PPIs with steroidogenic and possibly other CYPs. Interestingly, the documented functional influence of PGRMC1 on various steroidogenic CYPs appeared to be generally positive.

The above mentioned ability of PGRMC1 to complex with CYP3A4 first indicated the possibility that PGRMC1 may also interact with drug metabolizing P450s ([@B18]). Although the authors emphasized the apparent existence of stoichiometric and physically stable complexes, it should be kept in mind that the experimental conditions of overexpressing tagged and manipulated proteins were quite artificial and that it is unknown, whether PGRMC1 abundance in the ER is sufficient for the formation of 1:1 complexes at higher concentrations.

Two studies have investigated the question whether PGRMC1 affects drug metabolizing CYPs functionally. Szczesna-Skorupa and Kemper, using cotransfection and coimmunoprecipitation of FLAG-tagged PGRMC1 with variously tagged rabbit CYP2C2 and human CYP2C8 and CYP3A4 in HEK293 cells could show efficient binding of PGRMC1 to all three CYPs, for CYP2C2 mainly mediated by the cytoplasmic domain ([@B53]). The effect of PGRMC1 on enzymatic activity was tested by siRNA-mediated downregulation of endogenous PGRMC1, and by coexpression with functional CYP plasmids in HEK293 and HepG2 hepatoma cells (**Table [1](#T1){ref-type="table"}**). Surprisingly, the results were quite opposite to those of steroidogenic CYPs, as CYP activities were either unchanged or slightly increased in PGRMC1-deficient cells, but decreased in presence of exogenously expressed PGRMC1. Interestingly, the inhibitory effect could be partially and CYP isoform-dependently reversed by increased expression of POR, also shown to directly interact with PGRMC1. The authors concluded that in contrast to steroidogenic CYPs, PGRMC1 is not required by drug metabolizing CYPs for enzymatic activity and that the CYP differential effects may be explained by the intricate PPI affinities in triple CYP-POR-PGRMC1 systems ([@B53]).

[@B44] found differential effects of PGRMC1 cotransfection with CYP2C9, CYP2E1, and CYP3A4 in HepG2 cells. While CYP3A4 had increased *K*~m~ and decreased *V*~max~ with two different substrates (testosterone and midazolam), CYP2C9 *K*~m~ was unchanged but *V*~max~ also decreased, and CYP2E1 activity (chlorzoxazone, 7-ethoxycoumarin) remained unchanged. The authors also confirmed direct interactions of PGRMC1 with all three CYPs ([@B44]).

More recently, [@B21] in their structural study investigated the relevance of heme-mediated dimerization on functional interactions with human CYPs. By incubation of FLAG-tagged PGRMC1 with microsomes from insect-cells expressing POR, CYB5, and either CYP1A2 or CYP3A4, they showed by immunoprecipitation that only wild-type PGRMC1 but not the Y113F mutant interacted with the present CYP. The interaction with CYP1A2 was furthermore blocked by incubation with a CO-generating reagent, indicating that PGRMC1 dimerization is necessary for the interaction. To test whether CYP-mediated enzymatic functions are affected they used HCT116 human colon cancer cells stably expressing control or PGRMC1 shRNA to reduce endogenous PGRMC1 expression and incubated them with doxorubicin. PGRMC1 knock-down suppressed the conversion of doxorubicin to doxorubicinol, and increased cell sensitivity to doxorubicinol. This effect was partially reversed by coexpression of the wild-type PGRMC1 but not of the Y113F mutant. Assuming that CYP2D6 and CYP3A4 are the relevant enzymes for doxorubicinol-formation in HCT116 cells, the authors concluded that interaction of CYPs with the PGRMC1 dimer was a crucial component of CYP activity ([@B21]). However, this conclusion is severely flawed because the metabolic step from doxorubicin to doxorubicinol is not a hydroxylation but in fact a 2-electron reduction of a ketogroup to an aliphatic alcohol. This reduction is not catalyzed by CYPs 2D6 and 3A4 as indicated in the paper, but mainly by cytosolic carbonyl reductase 1 ([@B24]). Furthermore the use of HCT116 cells with very low CYP3A4 expression seems inappropriate for CYP metabolism studies ([@B13]). We therefore believe that this and other previously reported functional and cellular effects of PGRMC1 on doxorubicin-metabolism or cytotoxicity (e.g., [@B11]; [@B32]) are not due to interactions with CYPs but must have other reasons.

Finally the recent study by [@B48] should be mentioned here again as it demonstrated a role of PGRMC1 in heme homeostasis and its ability to directly transfer heme to CYB5 *in vitro*. The authors suggest that PGRMC1 may be a heme chaperone or sensor, and this could of course have additional direct or indirect implications for CYP function (**Figure [1](#F1){ref-type="fig"}**).

PGRMC2
------

Despite its high similarity to PGRMC1 much less is known about PGRMC2 ([@B55]). The first observation indicating a role in CYP function was made in a pharmacogenetic screen in human livers, where an intronic PGRMC2 polymorphism (rs3733260) was significantly associated with lower levels of mRNA expression, protein and enzyme activity ([@B28]). Although the directionality of this influence was the same as that observed for PGRMC1 and CYP3A4, it should be noted that the data are correlative in nature and would also be compatible with gene regulatory mechanisms (**Figure [1](#F1){ref-type="fig"}**). Stable physical interactions of PGRMC2 were demonstrated in human embryonic kidney cells for CYP1A2 and CYP3A4, suggesting similar interaction potential as for PGRMC1 ([@B3]). It should thus be interesting to investigate the potential of PGRMC2 to modulate CYP function and/or expression in a valid system.

Neudesin and Neuferricin
------------------------

To our knowledge, only one study ([@B5]) directly addressed the potential interaction of these proteins with CYPs. The authors showed that neuferricin is colocalized with POR in HeLa cells. Neuferricin knockdown reduced endogenous CYP51A1 (lanosterol demethylase) protein levels, which lead to increased sensitivity toward mevalonate, an intermediate of the cholesterol synthesis pathway. This suggested a stabilizing role of neuferricin for CYP51A1, as previously described for PGRMC1 and Dap1 ([@B18]). Data further indicated that neuferricin knockdown also decreased the fraction of endogenous CYP3A4 activity that was enhanced by overexpressed POR, indicating activation of CYP3A4 by neuferricin, in contrast to the inhibitory effects of PGRMC1 (see above). However, it should be pointed out that the neuferricin data consists of a single point measurement carried out in a cell model that is not usually applied for drug metabolism studies, leaving it unclear whether the conclusion can be generalized. The same argument applies to the studies on HeLa cell exposure to chemotherapeutic agents such as paclitaxel, cisplatin, and doxorubicin, which resulted in increased sensitivities in CYB5D2 deficient cells ([@B5]). Since the expression levels of drug metabolizing CYPs are very low in HeLa cells, the construction of a link between CYB5D2 and function of drug metabolizing CYPs based on these data is in our opinion questionable.

Conclusion and Future Perspectives
==================================

Direct physical interactions of MAPRs, especially of mammalian PGRMC1 or yeast Dap1, with various cytochromes P450 are strongly supported by experimental data. However, data are still limited and in our view use of inappropriate model systems questions some conclusions on functional interactions with CYPs. Open questions that remain to be studied are, for example: which direct MAPR-CYP interactions are possible in binary, ternary, and higher order complexes and how do they affect function; how could MAPRs indirectly influence CYP function, e.g., by regulating heme supply and protein stability; are there MAPR signaling pathways that affect transcriptional regulation of CYPs and possibly other drug metabolizing enzymes, etc. It is of eminent importance that valid experimental systems, which express the CYP system at physiological levels, e.g., primary hepatocytes or genetically modified mice, are used in future studies.
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